Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels
Open Access
- 1 November 1997
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 76 (9) , 1221-1227
- https://doi.org/10.1038/bjc.1997.537
Abstract
Vascular endothelial growth factor (VEGF) is known to be produced by various solid tumours and is thought to be involved in microvascular permeability and/or angiogenesis. To examine the relationship between VEGF expression in ovarian neoplasms and clinicopathological factors or patient survival, expression of VEGF was analysed immunohistochemically in 110 epithelial ovarian tumours. In addition, VEGF levels in the tumour fluid (17 patients), ascites (12 patients) and sera (38 patients) were determined using enzyme immunoassay. Positive immunostaining for VEGF was observed in 97% (68 out of 70) of ovarian carcinomas, which was significantly higher than that of tumours of low malignant potential (LMP) (13 out of 25; 52%) and benign cystadenomas (5 out of 15; 33%) (P < 0.01). In ovarian carcinomas, strong VEGF immunostaining was also observed more frequently in tumours of clear cell type (P < 0.05) in the advanced stage of disease (P < 0.05) and with positive peritoneal cytology (P < 0.01). Patients with strong VEGF staining had poorer survival rates than those with weak or no immunostaining for VEGF (P < 0.01). These findings suggest that strong VEGF expression plays an important role in the tumour progression of ovarian carcinoma. The enzyme immunoassay revealed higher serum VEGF levels in carcinoma patients than those in patients with LMP or benign tumours (P < 0.01). Serum VEGF levels decreased after the successful removal of tumours in ovarian cancer patients and, in one patient, the serum VEGF level was re-elevated during relapse. Therefore, serum VEGF could be used as a marker for monitoring the clinical course of ovarian cancer patients.Keywords
This publication has 23 references indexed in Scilit:
- Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation.1995
- Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis.1994
- Vascular permeability factor gene expression in normal and neoplastic human ovaries.1994
- Vascular endothelial growth factor and its receptorsProgress in Growth Factor Research, 1994
- Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas.1993
- Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract.1993
- Vascular permeability factor (VPF, VEGF) in tumor biologyCancer and Metastasis Reviews, 1993
- Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions.1993
- Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivoNature, 1992
- HUMAN VASCULAR-PERMEABILITY FACTOR - ISOLATION FROM U937-CELLS1989